ImmunityBio (Nasdaq:IBRX) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

IBRX 주식 개요

임상 단계의 생명공학 회사인 이뮤니티바이오는 암과 전염병을 퇴치하기 위해 자연 면역 체계를 강화하는 치료법과 백신을 개발하는 기업입니다.

IBRX 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	2/6
과거 실적	0/6
재무 상태	0/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 86.1% 에서 거래

수익은 연간 48.93% 증가할 것으로 예상됩니다.

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

최근 3개월간 주가 변동폭 심해

cash runway 경력이 1년 미만입니다.

마이너스 주주 지분

+ 2 더 많은 위험

ImmunityBio, Inc. 경쟁사

Nuvalent

NasdaqGS:NUVL

US$4.9b

Immunovant

NasdaqGS:IMVT

US$3.9b

Merus

NasdaqGM:MRUS

US$3.9b

Avidity Biosciences

NasdaqGM:RNA

US$4.3b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 ImmunityBio
과거 주가
현재 주가	US$6.32
52주 최고치	US$10.53
52주 최저치	US$1.25
베타	-0.31
11개월 변경	-1.56%
3개월 변경 사항	18.80%
1년 변경 사항	127.34%
33년 변화	-54.82%
5년 변화	n/a
IPO 이후 변화	-83.67%

최근 뉴스 및 업데이트

ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential

Jun 25

ImmunityBio: Anktiva's Launch Demands A Reassessment

Jun 06

Recent updates

주주 수익률

	IBRX	US Biotechs	US 마켓
7D	-12.9%	-0.7%	0.07%
1Y	127.3%	10.2%	20.7%

수익률 대 산업: IBRX 지난 1년 동안 6.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: IBRX 지난 1년 동안 23.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is IBRX's price volatile compared to industry and market?
IBRX volatility
IBRX Average Weekly Movement	18.9%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.8%

안정적인 주가: IBRX 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: IBRX 의 주간 변동성( 19% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
n/a	628	Rich Adcock	immunitybio.com

임상 단계의 생명공학 회사인 이뮤니티바이오는 암과 전염병을 퇴치하기 위해 자연 면역 체계를 강화하는 치료법과 백신을 개발하는 회사입니다. 이 회사의 생물학적 제품 후보 개발을 위한 플랫폼에는 항체-사이토카인 융합 단백질, DNA, RNA 및 재조합 단백질 백신, 세포 치료제가 포함됩니다. 이 회사의 플랫폼은 방광암, 폐암, 대장암, 다형성 교모세포종 등 액체 및 고형 종양의 다양한 적응증에 대해 현재 임상시험 중이거나 계획 중인 치료제를 개발했습니다.

ImmunityBio, Inc. 기본 사항 요약

ImmunityBio 의 수익과 매출은 시가총액과 어떻게 비교하나요?
IBRX 기본 통계
시가총액	US$4.37b
수익(TTM)	-US$600.96m
수익(TTM)	US$302.00k

Over9,999x

P/S 비율

-7.3x

P/E 비율

IBRX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
IBRX 손익 계산서(TTM)
수익	US$302.00k
수익 비용	US$0
총 이익	US$302.00k
기타 비용	US$601.26m
수익	-US$600.96m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.87
총 마진	100.00%
순이익 마진	-198,994.04%
부채/자본 비율	-123.2%

IBRX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

IBRX 주식 개요

보상

위험 분석

ImmunityBio, Inc. 경쟁사

NasdaqGS:NUVL

US$4.9b

NasdaqGS:IMVT

US$3.9b

NasdaqGM:MRUS

US$3.9b

NasdaqGM:RNA

US$4.3b

가격 내역 및 성능

최근 뉴스 및 업데이트

ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential

ImmunityBio, Inc. Announces the Initial Treatment of Multiple Patients in the United States to Receive Therapy with ANKTIVA

ImmunityBio: Anktiva's Launch Demands A Reassessment

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

Consensus revenue estimates increase by 639%, EPS downgraded

Recent updates

ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential

ImmunityBio, Inc. Announces the Initial Treatment of Multiple Patients in the United States to Receive Therapy with ANKTIVA

ImmunityBio: Anktiva's Launch Demands A Reassessment

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

Consensus revenue estimates increase by 639%, EPS downgraded

ImmunityBio, Inc., Annual General Meeting, Jun 11, 2024

ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle

Insufficient new directors

Consensus revenue estimates increase by 25%

No longer forecast to breakeven

New minor risk - Profitability

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmunityBio Announces Data from A Phase 1 Pilot Study

ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise

New major risk - Share price stability

ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Forecast to breakeven in 2026

ImmunityBio: Buy Low Now Vs. Buy High Later

Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes (PROs) of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG

Consensus revenue estimates decrease by 54%, EPS upgraded

New major risk - Financial position

ImmunityBio, Inc. Announces First Data for Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-Tumor Activity

ImmunityBio, Inc. Announces U.S. Food and Drug Administration Accepts its BLA Resubmission as Complete and Sets New PDUFA Date

New major risk - Share price stability

ImmunityBio, Inc. Announces Biological License Application Resubmission for N-803 in BCG Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ

New major risk - Shareholder dilution

ImmunityBio, Inc. announced that it has received $200 million in funding from Nant Capital, LLC

ImmunityBio, Inc. announced that it has received $200 million in funding from Nant Capital, LLC

Consensus revenue estimates increase by 20%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Jakubowitz Law Reminds Immunitybio Shareholders of A Lead Plaintiff Deadline of August 29, 2023

ImmunityBio, Inc. Appoints Enrique Diloné as Chief Technology Officer, Effective August 14, 2023

ImmunityBio, Inc. Announces Findings from a Phase 1 Study Showing Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells

Pomerantz Law Firm Announces the Filing of a Class Action Against ImmunityBio, Inc. and Certain Officers – IBRX

Independent Director recently bought US$71k worth of stock

ImmunityBio, Inc., Annual General Meeting, Jun 13, 2023

ImmunityBio, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration Regarding Its Biologics License Application

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

President exercised options and sold US$183k worth of stock

ImmunityBio, Inc. announced that it expects to receive $50 million in funding

Price target decreased to US$9.00

High number of new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmunityBio: PDUFA Pending

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.23 loss in 2Q 2021)

ImmunityBio: Compelling Data In Bladder Cancer, Yet Funding Issues Remain

Consensus forecasts updated

ImmunityBio, Inc. Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma in Situ

ImmunityBio, Inc. Announces Quilt Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer

ImmunityBio: Ready To Shift Gears After Long-Awaited BLA Submission

ImmunityBio, Inc. Submits Biologics License Application for N-803 Plus Bcg for Patients with Bcg-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

First quarter 2022 earnings: EPS and revenues miss analyst expectations

ImmunityBio, Inc., Annual General Meeting, Jun 14, 2022

Price target decreased to US$20.00